Effect of transdermal tulobuterol added to inhaled corticosteroids in asthma patients

Allergology International

Volumn 54, Issue 4, 2005, Pages 615-620

  Tamura, Gen ^a   Sano, Yasuyuki ^b   Hirata, Kazuto ^d   Ishioka, Shinichi ^e   Nakashima, Mitsuyoshi ^f   Miyamoto, Terumasa ^c  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b Doai Memorial Hospital   (Japan)

^c Japan Clinical Allergy Research Institute   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Ishioka Clinic   (Japan)

^f Hamamatsu Institute of Clinical Pharmacology and Therapeutics   (Japan)

Author keywords

Bronchial asthma; Long acting 2 agonist; Transdermal therapeutic system; Tulobuterol tape

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PLACEBO; TULOBUTEROL;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DERMATITIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; THIRST; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

EID: 33846850053     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.54.615     Document Type: Article

References (24)

1. National Institutes of Health, National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Publication no. 97-405. Bethesda:National Institutes of Health, 1997.
2. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998;157:S1-53.
3. Inoue T, Murayama N, Toyoshima K, Kameda M, Takamatsu I, Doi S. Early intervention with inhaled steroids in childhood asthma. Allergol. Int. 2004;53:309-314.
4. National Institutes of Health, National Heart Lung and Blood Institute. Global Initiative for Asthma. Global strategy for asthma management and prevention. Publication no. NIH-NHLI 02-3659. Bethesda:National Institutes of Health, 2002.
5. Uematsu T, Nakano M, Kosuge K, Kanamaru M, Nakashima M. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur. J. Clin. Pharmacol. 1993;44:361-364.
6. Miyamoto T, Takishima T, Takahashi T, Nakajima S, Yamakido M, Nakajima M. [Clinical evaluation of HN-078, a patch formulation of tulobuterol, in patients with bronchial asthma on the late phase II study.] [J. Clin. Therap. Med.] 1995;11:761-782 (in Japanese).
7. Miyamoto T, Takishima T, Takahashi T, Nakajima S, Yamakido M, Nakajima M. [Clinical evaluation of HN-078, a patch formulation of tulobuterol, in patients with bronchial asthma on the phase III study.] [J. Clin. Therap. Med.] 1995;11:783-807 (in Japanese).
8. Kume H, Kondo M, Ito Y, Suzuki R, Yamaki K, Takagi K. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. Clin. Exp. Pharmacol. Physiol. 2002;29:1076-1083.
9. Suko M. [Clinical evaluation of HN-078, a patch formulation of tulobuterol, on morning dipping with adult bronchial asthma.] [J. Clin. Therap. Med.] 1995;11:809-818(in Japanese).
10. Iikura Y, Uchiyama H, Akimoto K et al. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Ann. Allergy Asthma Immunol. 1995;74:147-151.
11. Linden A, Rabe KF, Lofdahl CG. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lung 1996;174:1-22.
12. Naline E, Zhang Y, Qian Y et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur. Respir. J. 1994;7:914-920.
13. Jeppsson AB, Kallstrom BL, Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol. Toxicol. 1992;71:272-277.
14. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224.
15. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996;153:1481-1488.
16. Kelsen SG, Church NL, Gillman SA et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J. Asthma 1999;36:703-715.
17. Murray JJ, Church NL, Anderson WH et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc. 1999;20:173- 180.
18. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann. Allergy Asthma Immunol. 1999;82:383-389.
19. Wilding P, Clark M, Thompson Coon J et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997;314:1441-1446.
20. Nielsen LP, Pedersen B, Faurschou P, Madsen F, Wilcke JT, Dahl R. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir. Med. 1999;93:863-868.
21. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl J. Med. 1997;337:1405-1411.
22. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am. Rev. Respir. Dis. 1987;136:225-244.
23. Crompton GK, Ayres JG, Basran G et al. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 1999;159:824-828.
24. Tamura G, Yamauchi K, Honma M et al. [Long term study of HN-078, a patch formulation of tulobuterol, in adult bronchial asthma.] [J. Clin. Therap. Med.] 1995;11:1067-1080 (in Japanese).